Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Ischemic Stroke Clinical Trial

Official title:

Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke(AXAIS): A Multicenter, Randomized, Open-label, Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04813445
• Other study ID #: 2018YFC1705001-05
• Status: Recruiting
• Phase: N/A
• Start date: May 28, 2021
• Est. completion date: September 28, 2022

Study information

• Verified date: February 2022
• Source: Dongzhimen Hospital, Beijing
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this trial is to analyse the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke by Metabonomics, proteomics and clinical parameters.

Description:

Xingnaojing is widely used in China, but there is lack of sufficient and reasonable explanation of its intervention effects for acute ischemic stroke currently. The primary hypothesis of this trial is that , Compared with the blank control group, Xingnaojing will produce serial changes in plasma and urine metabolites and biomarkers at baseline (pre-dose), 8 days and 11days . The serial changes may be the potential support to explain the intervention effect of Xingnaojing. All participants will have a National Institutes of Health Stroke Scale(NIHSS)entry score of 4-25. Participants who have planned or already received the intravenous thrombolysis or endovascular treatment will be excluded. The primary outcome will be determined at 11 days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72
• Est. completion date: September 28, 2022
• Est. primary completion date: June 28, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 80 Years

Eligibility

Inclusion Criteria:

• Diagnosis of Acute ischemic stroke;

• Symptom onset within 24 hours;

• 35 = Age = 80 years;

• 4 = NIHSS = 25;

• Patient or legally authorized representative has signed informed consent.

Exclusion Criteria:

• Expected length of hospital stay is less than 10 days;

• Planned or already receiving intravenous thrombolysis or endovascular treatment;

• Use of drugs with unknown composition within 1 week before enrollment;

• Patients with acute infectious diseases (e.g. acute pneumonia) or taking related drugs within 1 month before treatment in the group;

• Suspected secondary stroke caused by tumor, brain trauma, or hematological diseases;

• Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scale score = 2) ;

• Other conditions that cause cardiogenic embolism (e.g., atrial fibrillation, rheumatic heart disease, valvular heart disease);

• Other conditions that lead to motor dysfunction (e.g., severe osteoarthrosis, rheumatoid arthritis);

• Significant renal or hepatic insufficiency (defined as a serum creatinine concentration, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) value that is twice the upper limit of normal);

• Life expectancy of 3 months or less due to other life-threatening illness (e.g.,advanced cancer)

• Other conditions that render outcomes or follow-up unlikely to be assessed;

• Known to be pregnant or breastfeeding;

• Currently receiving an investigational drug.

Related Conditions & MeSH terms

• Acute Stroke
• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Drug:
• Xingnaojing injection
Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.

Locations

Country	Name	City	State
China	Dongzhimen Hospital	Beijing	Beijing

Sponsors (4)

Lead Sponsor	Collaborator
Dongzhimen Hospital, Beijing	Affiliated Hospital of Chengde Medical University, Affiliated Hospital of Nantong University, Nanjing Brian Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The change of NIHSS score	The NIHSS score ranges from 0 (best score) to 42 (worst score).	Baseline, 3 days, 7 days and 10 days
Secondary	The proportion of NIHSS score from 0 to 1	The NIHSS score ranges from 0 (best score) to 42 (worst score).	Baseline, 3 days, 7 days and 10 days
Secondary	Patient reported outcome (PRO) scale of stroke	Patient reported outcome (PRO) scale of stroke at 10 days.The PRO score ranges from 0(worst score) to 180 (best score).	10 days
Secondary	The proportion of patients independent at 30 days and 90 days	The proportion of patients independent is defined as Modified Rankin Scale score of 0, 1, or 2. The mRS score ranges from 0 (best score) to 6 (worst score).	30 days and 90 days
Secondary	Cardio-cerebral vascular incident	Cardio-cerebral vascular incident were defined as stroke, acute coronary syndrome (acute ST-elevation myocardial infarction, acute non-ST-elevation myocardial infarction and unstable angina), vascular death, etc.	Within baseline and 90 days
Secondary	The difference in proteomic and metabolomics	Through proteomics and metabonomics to explore whether there are different metabolites or proteins between the two groups.(It's not known whether there are differences in the human body between the two groups.We are in the exploratory stage.)	baseline (pre-dose), 7 days and 11days
Secondary	State of consciousness	The state of consciousness evaluated by Glasgow Coma Scale at Baseline, 3 days, 7 days and 10 days. The Glasgow score ranges from 3(worst score) to 15 (best score).	Baseline, 3 days, 7 days and 10 days
Secondary	Activities of daily living	Activities of daily living will be measured by Barthel Index score at 30 days and 90 days.The Barthel Index score ranges from 0 (worst score) to 100 (best score).	30 days and 90 days
Secondary	Safety end points	Number of patients with any adverse events, results of electrocardiography, vital signs and laboratory tests (complete blood count, chemistry and urinalysis).	10 days
Secondary	Stroke related deaths and deaths from any cause	Stroke related deaths and deaths from any cause within 10 days and 90 days after symptom onset.	Within 10 days and 90 days